Genetic Kidney Disorders Therapeutics
1. Rivfloza patent expiration
Treatment: Method of treating primary hyperoxaluria type 1 (ph1)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11286488 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(12 years from now) | |
| US10738311 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US11359203 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US11661604 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(12 years from now) | |
| US11053502 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US10351854 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 27, 2028 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-443) | Sep 29, 2030 |
Drugs and Companies using NEDOSIRAN SODIUM ingredient
NCE-1 date: 30 September, 2027
Market Authorisation Date: 29 September, 2023
Dosage: SOLUTION
More Information on Dosage
RIVFLOZA family patents
